Siam Piwat Group has reaffirmed its leadership in world-class experiential destinations by securing over 20 prestigious accolades from leading Thai and international media and institutions since the ...

QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...

The market seems to share this optimistic view, since Qiagen has a short interest of only 1.9% (this is the percentage of the ...

Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use. This marks Qiagen’s second ...

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further ...

Qiagen alleges that BioMérieux infringes a European patent that protects the company's QuantiFeron interferon-gamma release assay technology for latent TB detection.

We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now. In this article, we are going to take a look at ...

Qiagen (QGEN) announced that it has filed a complaint against bioMerieux for patent infringement. The complaint, filed in the Local Division of ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.

Investment analysts at Zacks Research cut their Q1 2025 earnings per share estimates for Qiagen in a research note issued on Wednesday, February 26th. Zacks Research analyst R. Department now expects ...